Generating destination analysis
Compass Direction
Earnings IntelligenceAI-Powered
Compass Score
Unlock Full LLY Analysis
UpgradeKey Numbers
Market Cap
$750B
P/E
65
Revenue Growth
+32.0%
Gross Margin
N/A
ROE
N/A
About Eli Lilly and Company
Eli Lilly and Company (LLY) is a mega-cap NYSE-listed company in the pharma space, blending biotech and genomics initiatives alongside its core business operations. Pharma giant leading the GLP-1 revolution with Mounjaro and Zepbound weight-loss drugs. Valued at 65x trailing earnings with a $750B market capitalization, Eli Lilly and Company has delivered rapid top-line expansion with revenue moving +32% over the past year.
Expert Coverage
Price & Technical Analysis
Price vs 200DMA
DMA Convergence
50 DMA
200 DMA
More in Biotech & Genomics
ARK Genomic Revolution ETF
ETF focused on companies advancing genomics, gene editing, and therapeutics.
DexCom Inc.
Continuous glucose monitoring leader expanding beyond diabetes management.
Alnylam Pharmaceuticals
RNA interference therapeutics leader with approved treatments for rare diseases.
Beam Therapeutics
Base editing platform with differentiated gene-editing pipeline.